{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:23:04Z","timestamp":1789172584760,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W006804\/1"],"award-info":[{"award-number":["MR\/W006804\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cellsig.2023.110689","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T02:42:18Z","timestamp":1682649738000},"page":"110689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Phosphodiesterase 7 as a therapeutic target \u2013 Where are we now?"],"prefix":"10.1016","volume":"108","author":[{"given":"Alina","family":"Zorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2023.110689_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellsig.2023.110689_bb0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1006\/bbrc.2000.2661","article-title":"Identification of human PDE7B, a cAMP-specific phosphodiesterase","volume":"271","author":"Sasaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2023.110689_bb0015","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases: inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellsig.2023.110689_bb0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bph.12308","article-title":"Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis","volume":"170","author":"Gonz\u00e1lez-Garc\u00eda","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0025","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1006\/bbrc.1993.1722","article-title":"A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines","volume":"193","author":"Ichimura","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2023.110689_bb0035","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1016\/S0021-9258(18)31474-1","article-title":"Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae","volume":"268","author":"Michaeli","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.cellsig.2023.110689_bb0045","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neurobiolaging.2014.10.008","article-title":"Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice","volume":"36","author":"Morales-Garcia","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cellsig.2023.110689_bb0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bj3610211","article-title":"Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation","volume":"361","author":"Sasaki","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.cellsig.2023.110689_bb0055","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1073\/pnas.97.1.472","article-title":"Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase","volume":"97","author":"Hetman","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0060","first-page":"L279","article-title":"Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells","volume":"284","author":"Smith","year":"2003","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.cellsig.2023.110689_bb0065","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/stem.2480","article-title":"Phosphodiesterase7 inhibition activates adult neurogenesis in Hippocampus and subventricular zone in vitro and in vivo","volume":"35","author":"Morales-Garcia","year":"2017","journal-title":"Stem Cells"},{"key":"10.1016\/j.cellsig.2023.110689_bb0070","doi-asserted-by":"crossref","first-page":"16152","DOI":"10.1074\/jbc.272.26.16152","article-title":"Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart *","volume":"272","author":"Han","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0075","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1073\/pnas.101131098","article-title":"T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3","volume":"98","author":"Glavas","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0080","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00018-013-1340-2","article-title":"Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival","volume":"70","author":"Medina-Rodr\u00edguez","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0085","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/bbrc.2000.2743","article-title":"Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase","volume":"272","author":"Gardner","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2023.110689_bb0090","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.1073\/pnas.0806152105","article-title":"Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2023.110689_bb0095","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-022-01072-1","article-title":"Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders","author":"Khan","year":"2022","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.cellsig.2023.110689_bb0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellsig.2023.110689_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2011.10.040","article-title":"Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model","volume":"47","author":"Redondo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","article-title":"Cyclic AMP master regulator of innate immune cell function","volume":"39","author":"Serezani","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0115","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011148","article-title":"The cyclic AMP pathway","volume":"4","author":"Sassone-Corsi","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1124\/pr.110.003707","article-title":"Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions","volume":"65","author":"Schmidt","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cellsig.2023.110689_bb0125","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/bph.15403","article-title":"The role of Popeye domain-containing protein 1 (POPDC1) in the progression of the malignant phenotype","volume":"179","author":"Tucker","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1124\/pr.117.014035","article-title":"The hyperpolarization-activated cyclic nucleotide\u2013gated channels: from biophysics to pharmacology of a unique family of ion channels","volume":"69","author":"Sartiani","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cellsig.2023.110689_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003960","article-title":"CRIS\u2014A novel cAMP-binding protein controlling Spermiogenesis and the development of flagellar bending","volume":"9","author":"Kr\u00e4hling","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cellsig.2023.110689_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cellimm.2009.04.005","article-title":"Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells","volume":"258","author":"Goto","year":"2009","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0145","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.283.5403.848","article-title":"CD3- and CD28-dependent induction of PDE7 required for T cell activation","volume":"283","author":"Li","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2023.110689_bb0150","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.4049\/jimmunol.171.12.6414","article-title":"Phosphodiesterase 7A-deficient mice have functional T cells","volume":"171","author":"Yang","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0155","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1111\/bph.13192","article-title":"PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis","volume":"172","author":"Mestre","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017240","article-title":"Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease","volume":"6","author":"Morales-Garcia","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2023.110689_bb0165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/15622975.2022.2086297","article-title":"The habenular volume and PDE7A allelic polymorphism in major depressive disorder: preliminary findings","volume":"24","author":"Aftanas","year":"2023","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.cellsig.2023.110689_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.nlm.2020.107357","article-title":"Pharmacological inhibition of phosphodiesterase 7 enhances consolidation processes of spatial memory","volume":"177","author":"McQuown","year":"2021","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110655","article-title":"Neuronal lack of PDE7a disrupted working memory, spatial learning, and memory but facilitated cued fear memory in mice","volume":"120","author":"Liu","year":"2023","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.cellsig.2023.110689_bb0180","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1016\/j.bmcl.2012.07.077","article-title":"Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson\u2019s disease model","volume":"22","author":"Banerjee","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2023.110689_bb0185","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-018-0352-4","article-title":"Amyloid \u03b2-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition","volume":"10","author":"Bartolome","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cellsig.2023.110689_bb0190","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.neurobiolaging.2013.03.011","article-title":"Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer\u2019s disease","volume":"34","author":"Perez-Gonzalez","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cellsig.2023.110689_bb0195","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1021\/jm201720d","article-title":"Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds","volume":"55","author":"Redondo","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/0972-2327.104323","article-title":"Hippocampus in health and disease: an overview","volume":"15","author":"Anand","year":"2012","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0205","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1021\/cn400166d","article-title":"Crosstalk between phosphodiesterase 7 and glycogen synthase Kinase-3: two relevant therapeutic targets for neurological disorders","volume":"5","author":"Morales-Garcia","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0210","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s12035-019-01745-z","article-title":"Phosphodiesterase 7 regulation in cellular and rodent models of Parkinson\u2019s disease","volume":"57","author":"Morales-Garcia","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0215","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/cn300182g","article-title":"Glycogen synthase Kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease","volume":"4","author":"Morales-Garc\u00eda","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0220","series-title":"MDS Abstracts","article-title":"Targeting PDE7 by the small molecule S14: A potential disease-modifying Parkinson\u2019s disease therapy ready to start clinical trials [abstract]","volume":"vol. 31","author":"Martinez","year":"2016"},{"key":"10.1016\/j.cellsig.2023.110689_bb0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuropharm.2012.06.032","article-title":"Dual inhibitor of PDE7 and GSK-3 \u2013 VP1.15 acts as antipsychotic and cognitive enhancer in C57BL\/6J mice","volume":"64","author":"Lipina","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cellsig.2023.110689_bb0230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice","volume":"12","author":"Gines","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2023.110689_bb0235","series-title":"Phosphodiesterases: CNS Functions and Diseases","first-page":"285","article-title":"Role of phosphodiesterases in Huntington\u2019s disease","author":"Fusco","year":"2017"},{"key":"10.1016\/j.cellsig.2023.110689_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015937","article-title":"PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury","volume":"6","author":"Paterniti","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2023.110689_bb0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchemneu.2016.12.001","article-title":"A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice","volume":"80","author":"Mart\u00edn-\u00c1lvarez","year":"2017","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.cellsig.2023.110689_bb0250","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/cn300105c","article-title":"Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice","volume":"3","author":"Redondo","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0255","doi-asserted-by":"crossref","first-page":"14378","DOI":"10.3390\/ijms232214378","article-title":"The dual PDE7-GSK3\u03b2 inhibitor, VP3.15, as neuroprotective disease-modifying treatment in a model of primary progressive multiple sclerosis","volume":"23","author":"Ben\u00edtez-Fern\u00e1ndez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0265","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41388-018-0499-2","article-title":"Phosphodiesterase 7B\/microRNA-200c relationship regulates triple-negative breast cancer cell growth","volume":"38","author":"Zhang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.cellsig.2023.110689_bb0270","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.leukres.2013.02.006","article-title":"High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma","volume":"37","author":"Fang","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cellsig.2023.110689_bb0275","doi-asserted-by":"crossref","first-page":"16991","DOI":"10.1038\/s41598-019-53563-x","article-title":"The prognostic significance of PDE7B in cytogenetically normal acute myeloid leukemia","volume":"9","author":"Cao","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2023.110689_bb0280","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.1073\/pnas.0806152105","article-title":"Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0285","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/ijc.25785","article-title":"Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia","volume":"129","author":"Zhang","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellsig.2023.110689_bb0290","doi-asserted-by":"crossref","first-page":"15263","DOI":"10.1038\/s41598-018-31859-8","article-title":"BRCA1\/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impacts","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2023.110689_bb0295","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.1021\/jm501090m","article-title":"Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors","volume":"57","author":"Garc\u00eda","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0300","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/jm990382n","article-title":"Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors","volume":"43","author":"Mart\u00ednez","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112437","article-title":"Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A\/5-HT7 receptor antagonists and phosphodiesterase 4\/7 inhibitors with procognitive and antidepressant activity","volume":"201","author":"Jankowska","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0310","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ejps.2012.01.007","article-title":"5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood\u2013brain barrier penetration and binding to human serum albumin","volume":"45","author":"P\u00e9rez","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.cellsig.2023.110689_bb0315","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.bmcl.2004.07.011","article-title":"Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1","volume":"14","author":"Lorthiois","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2023.110689_bb0320","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1016\/j.bmcl.2004.07.010","article-title":"Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: optimization of 5,8-disubstituted derivatives","volume":"14","author":"Bernardelli","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2023.110689_bb0325","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cmdc.200900043","article-title":"Synthesis, structural analysis, and biological evaluation of Thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors","volume":"4","author":"Casta\u00f1o","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.cellsig.2023.110689_bb0330","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1016\/j.bmcl.2011.09.065","article-title":"Synthesis and structure\u2013activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors","volume":"21","author":"Gewald","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2023.110689_bb0335","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ejmech.2007.10.027","article-title":"CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example","volume":"43","author":"Castro","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0340","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/00005344-199612000-00018","article-title":"Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor","volume":"28","author":"Vemulapalli","year":"1996","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0345","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","article-title":"Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase*","volume":"273","author":"Fisher","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0350","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejmech.2013.10.035","article-title":"Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities","volume":"70","author":"Redondo","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0355","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: In vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.cellsig.2023.110689_bb0360","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1471-4159.2012.07866.x","article-title":"The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury","volume":"122","author":"Sus\u00edn","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cellsig.2023.110689_bb0365","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5966\/sctm.2014-0277","article-title":"Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in Hemiparkinsonian rats","volume":"4","author":"Morales-Garcia","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.cellsig.2023.110689_bb0370","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/ijms22063206","article-title":"Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles","volume":"22","author":"Nozal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cellsig.2023.110689_bib371","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1021\/acschemneuro.0c00106","article-title":"PDE-7 inhibitor BRL-50481 reduces neurodegeneration and long-term memory deficits in mice following sevoflurane exposure","volume":"11","author":"Chen","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"6","key":"10.1016\/j.cellsig.2023.110689_bib372","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Mol. Pharmacol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656823001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656823001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:10:35Z","timestamp":1760267435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656823001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":76,"alternative-id":["S0898656823001031"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2023.110689","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase 7 as a therapeutic target \u2013 Where are we now?","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2023.110689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110689"}}